Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Income towards Parent Company (2022 - 2025)

Historic Income towards Parent Company for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to -$53.2 million.

  • ARS Pharmaceuticals' Income towards Parent Company fell 14458.34% to -$53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.8 million, marking a year-over-year decrease of 5004.46%. This contributed to the annual value of $8.0 million for FY2024, which is 11471.17% up from last year.
  • ARS Pharmaceuticals' Income towards Parent Company amounted to -$53.2 million in Q3 2025, which was down 14458.34% from -$47.6 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Income towards Parent Company ranged from a high of $47.2 million in Q4 2024 and a low of -$53.2 million during Q3 2025
  • Over the past 4 years, ARS Pharmaceuticals' median Income towards Parent Company value was -$15.4 million (recorded in 2022), while the average stood at -$16.3 million.
  • In the last 5 years, ARS Pharmaceuticals' Income towards Parent Company plummeted by 22476.36% in 2023 and then soared by 56153.92% in 2024.
  • ARS Pharmaceuticals' Income towards Parent Company (Quarter) stood at -$15.4 million in 2022, then soared by 33.78% to -$10.2 million in 2023, then surged by 561.54% to $47.2 million in 2024, then plummeted by 212.7% to -$53.2 million in 2025.
  • Its Income towards Parent Company was -$53.2 million in Q3 2025, compared to -$47.6 million in Q2 2025 and -$37.2 million in Q1 2025.